Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromes

Cancer Genetics

Volumn 204, Issue 11, 2011, Pages 603-628

  Kolquist, Kathryn A ^a   Schultz, Roger A ^b   Furrow, Aubry ^b   Brown, Theresa C ^c   Han, Jin Yeong ^d   Campbell, Lynda J ^e   Wall, Meaghan ^e   Slovak, Marilyn L ^b,f   Shaffer, Lisa G ^b   Ballif, Blake C ^b  

^a SACRED HEART MEDICAL CENTER   (United States)

^b PerkinElmer   (United States)

^c CSI Laboratories   (United States)

^d Dong A University College of Medicine   (South Korea)

^e ST VINCENT S HOSPITAL   (Australia)

^f QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

ACGH; Copy number alterations; MDS; Microarray based comparative genomic hybridization; Myelodysplastic syndromes

Indexed keywords

GENOMIC DNA; MICRORNA; OLIGONUCLEOTIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CCND1 GENE; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CHROMOSOME REARRANGEMENT; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE COURSE; DNA MICROARRAY; DNMT3A GENE; FIP1L1 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC GAIN; HRAS GENE; HUMAN; HUMAN TISSUE; KARYOTYPE; KARYOTYPING; MALIGNANT TRANSFORMATION; MOLECULARLY TARGETED THERAPY; MYELODYSPLASTIC SYNDROME; PDGFRA GENE; PRIORITY JOURNAL; RUNX1 GENE; TET2 GENE; TUMOR GENE; TUMOR SUPPRESSOR GENE; GENETICS; METHODOLOGY; NEOPLASM;

ABNORMAL KARYOTYPE; CHROMOSOME ABERRATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; HUMANS; MYELODYSPLASTIC SYNDROMES; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 84857099656     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2011.10.004     Document Type: Article

References (50)

1. Ma X., Does M., Raza A., et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007, 109:1536-1542.
2. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
3. Germing U., Hildebrandt B., Pfeilstocker M., et al. Refinement of the International Prognostic Scoring System (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005, 19:2223-2231.
4. Haase D., Germing U., Schanz J., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110:4385-4395.
5. Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol 2008, 87:515-526.
6. Rollison D.E., Howlader N., Smith M.T., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008, 112:45-52.
7. Gondek L.P., Tiu R., O'Keefe C.L., et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008, 111:1534-1542.
8. O'Keefe C.L., Tiu R., Gondek L.P., et al. High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes. Exp Hematol 2007, 35:240-251.
9. Makishima H., Rataul M., Gondek L.P., et al. FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q). Leuk Res 2010, 34:447-453.
10. Thiel A., Beier M., Ingenhag D., et al. Comprehensive array CGH of normal karyotype myelodysplastic syndromes reveals hidden recurrent and individual genomic copy number alterations with prognostic relevance. Leukemia 2011, 25:387-399.
11. Baldus C.D., Liyanarachchi S., Mrozek K., et al. Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes. Proc Natl Acad Sci U S A 2004, 101:3915-3920.
12. Gaidzik VI, Wang C, Schlenk RF, et al. Analysis of the ETS Family Member Genes ERG, ETS2, ETS1 and FLI1 in Acute Myeloid Leukemia (AML) Patients with Normal Cytogenetics: Expression Levels and Impact On Clinical Outcome. A Study of the AMLSG. 51st American Society of Hematology Annual Meeting Abstracts 2009;114:1600. Poster I622.
13. Kwon J., Seo Y., Ahn W. Recognition of potential predictive markers for diagnosis in Korean serous ovarian cancer patients at stage IIIc using array comparative genomic hybridization with high resolution. Molecular & Cellular Toxicology 2011, 7:77-86.
14. Li L., Chen X.P., Li Y.J. MicroRNA-146a and human disease. Scand J Immunol 2010, 71:227-231.
15. Barlow J.L., Drynan L.F., Trim N.L., et al. New insights into 5q- syndrome as a ribosomopathy. Cell Cycle 2010, 9:4286-4293.
16. Graubert T.A., Payton M.A., Shao J., et al. Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS One 2009, 4:e4583.
17. MacKinnon R.N., Kannourakis G., Wall M., et al. A cryptic deletion in 5q31.2 provides further evidence for a minimally deleted region in myelodysplastic syndromes. Cancer Genet 2011, 204:187-194.
18. Borer R.A., Lehner C.F., Eppenberger H.M., et al. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989, 56:379-390.
19. Dumbar T.S., Gentry G.A., Olson M.O. Interaction of nucleolar phosphoprotein B23 with nucleic acids. Biochemistry 1989, 28:9495-9501.
20. Colombo E., Marine J.C., Danovi D., et al. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 2002, 4:529-533.
21. Kurki S., Peltonen K., Latonen L., et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 2004, 5:465-475.
22. La Starza R., Matteucci C., Gorello P., et al. NPM1 deletion is associated with gross chromosomal rearrangements in leukemia. PLoS One 2010, 5:e12855.
23. Falini B., Mecucci C., Tiacci E., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005, 352:254-266.
24. Schnittger S., Schoch C., Kern W., et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005, 106:3733-3739.
25. Mackinnon R.N., Selan C., Wall M., et al. The paradox of 20q11.21 amplification in a subset of cases of myeloid malignancy with chromosome 20 deletion. Genes Chromosomes Cancer 2010, 49:998-1013.
26. O'Connor H.E., Butler T.A., Clark R., et al. Abnormalities of the ETV6 gene occur in the majority of patients with aberrations of the short arm of chromosome 12: a combined PCR and Southern blotting analysis. Leukemia 1998, 12:1099-1106.
27. Kita-Sasai Y., Horiike S., Misawa S., et al. International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. Br J Haematol 2001, 115:309-312.
28. Lai J.L., Preudhomme C., Zandecki M., et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia 1995, 9:370-381.
29. Lu D., Nounou R., Beran M., et al. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 2003, 97:441-449.
30. Williams V.C., Lucas J., Babcock M.A., et al. Neurofibromatosis type 1 revisited. Pediatrics 2009, 123:124-133.
31. Delhommeau F., Dupont S., Della Valle V., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360:2289-2301.
32. Ley T.J., Ding L., Walter M.J., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010, 363:2424-2433.
33. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214.
34. Dessen P, Le Minor S. GSTT1 (glutathione S-transferase theta 1). 2011. Available at: Acessed March 28, 2011. http://atlasgeneticsoncology.org/Genes/GC_GSTT1.html.
35. Dahabreh I.J., Giannouli S., Gota V., et al. GSTT1 and GSTM1 polymorphisms and myelodysplastic syndrome risk: a systematic review and meta-analysis. Int J Cancer 2010, 126:1716-1723.
36. Carim-Todd L., Escarceller M., Estivill X., et al. LRRN6A/LERN1 (leucine-rich repeat neuronal protein 1), a novel gene with enriched expression in limbic system and neocortex. Eur J Neurosci 2003, 18:3167-3182.
37. Kotliarov Y., Kotliarova S., Charong N., et al. Correlation analysis between single-nucleotide polymorphism and expression arrays in gliomas identifies potentially relevant target genes. Cancer Res 2009, 69:1596-1603.
38. Chi Y., Lindgren V., Quigley S., et al. Acute myelogenous leukemia with t(6;9)(p23;q34) and marrow basophilia: an overview. Arch Pathol Lab Med 2008, 132:1835-1837.
39. Kelly L.M., Kutok J.L., Williams I.R., et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci U S A 2002, 99:8283-8288.
40. Shibayama H., Takai E., Matsumura I., et al. Identification of a cytokine-induced antiapoptotic molecule anamorsin essential for definitive hematopoiesis. J Exp Med 2004, 199:581-592.
41. Sparano A., Quesnelle K.M., Kumar M.S., et al. Genome-wide profiling of oral squamous cell carcinoma by array-based comparative genomic hybridization. Laryngoscope 2006, 116:735-741.
42. Bock O., Muth M., Theophile K., et al. Identification of new target molecules PTK2, TGFBR2 and CD9 overexpressed during advanced bone marrow remodelling in primary myelofibrosis. Br J Haematol 2009, 146:510-520.
43. Eun S.Y., O'Connor B.P., Wong A.W., et al. Cutting edge: rho activation and actin polarization are dependent on plexin-A1 in dendritic cells. J Immunol 2006, 177:4271-4275.
44. Matteo Rigolin G., Howard J., Buggins A., et al. Phenotypic and functional characteristics of monocyte-derived dendritic cells from patients with myelodysplastic syndromes. Br J Haematol 1999, 107:844-850.
45. Gao X.N., Lin J., Li Y.H., et al. MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia. Oncogene 2011, 30:3416-3428.
46. Sridhar K., Ross D.T., Tibshirani R., et al. Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. Blood 2009, 114:4847-4858.
47. Ballif B.C., Rorem E.A., Sundin K., et al. Detection of low-level mosaicism by array CGH in routine diagnostic specimens. Am J Med Genet A 2006, 140:2757-2767.
48. Neill N.J., Torchia B.S., Bejjani B.A., et al. Comparative analysis of copy number detection by whole-genome BAC and oligonucleotide array CGH. Mol Cytogenet 2010, 3:11.
49. McKee K.K., Tan C.P., Palyha O.C., et al. Cloning and characterization of two human G protein-coupled receptor genes (GPR38 and GPR39) related to the growth hormone secretagogue and neurotensin receptors. Genomics 1997, 46:426-434.
50. Foltz D.R., Jansen L.E., Black B.E., et al. The human CENP-A centromeric nucleosome-associated complex. Nat Cell Biol 2006, 8:458-469.